Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Because chronic animal studies are costly and slow, engineering teams frequently receive in vivo data very late in product development. Consequently, issues like unexpected thrombosis or density mismatches are uncovered just prior to clinical trials, forcing abrupt redesigns between product generations.

Related Insights

While longer wear-time is a key market goal, it creates a development bottleneck. A clinical trial for a 30-day device inherently takes at least 30 days plus analysis time. This slows iteration to a crawl and makes it imperative to develop reliable lab tests that can serve as a proxy for real-world use.

The intense need to show positive clinical data to secure the next funding round forces biotech startups to prioritize speed over everything. Consequently, crucial but time-consuming manufacturability assessments are often postponed, viewed as an 'extra cost' that can be handled later, creating significant downstream technical debt.

Current drug development heavily relies on animal testing. However, significant biological differences mean we may be filtering out effective human medicines that fail in animal models, creating a hidden opportunity cost for medical breakthroughs.

A common failure mode is sprinting forward with a molecule after seeing any signal in an animal model. Isaac Stoner advises overinvesting in robust in-vitro assay development first. This ensures a deep understanding of a molecule's functional activity on human biology, preventing costly translational failures later.

Beyond establishing safety and efficacy, first-in-human trials provide crucial, practical insights unavailable from preclinical models. They reveal how a product fits into real surgical practice: if it's easy for surgeons to use, integrates into existing procedures, and requires additional training. This real-world validation is invaluable.

Engineering teams often default to hand-sewn stent covers in early phases because manual suturing is readily accessible and can be performed in-house. This initial convenience biases downstream architecture, committing programs to design constraints based on early prototyping ease rather than clinical optimization.

Clinical trials often just report success rates and discard failed devices. This is a missed opportunity. By contractually requiring failed devices to be returned, R&D teams can analyze failure modes and create representative lab tests, drastically speeding up development and avoiding expensive repeat clinicals.

The "Valley of Death" where most biotech companies fail is not due to bad science but to the crippling cost of animal trials, which are poor predictors of human outcomes. Parrish argues for shifting focus directly to human data, as mice are not a reliable biological proxy for humans.

The GIK solution (glucose, insulin, potassium) was known for decades and worked in animal studies where it was given immediately. It failed in human trials because it was administered six or more hours after a heart attack began. The key innovation was realizing the therapy's success hinges on immediate administration at the first sign of symptoms.

The primary obstacle in advancing protein design isn't creating better models, but the multi-week or multi-month delay in getting experimental validation from wet labs. This slow feedback loop fundamentally constrains the speed of research and model iteration, a problem the entire field is trying to solve.